类风湿关节炎甲氨蝶呤治疗后:三联疗法与依那西普的持久性比较
本研究为48周双盲非劣效随机试验的开放标签延伸随访,纳入353例甲氨蝶呤应答不佳的类风湿关节炎患者,随机接受三联疗法或甲氨蝶呤-依那西普治疗。结果显示三联疗法1年继续治疗的可能性为78%,高于甲氨蝶呤-依那西普的63%,且更多患者从依那西普方案转换为三联疗法(P=0.005),两种方案疾病活动度无差异。
要点
- 甲氨蝶呤应答不佳的RA患者中,三联疗法1年持续治疗率78%高于甲氨蝶呤-依那西普的63%。
- 从甲氨蝶呤-依那西普转换为三联疗法的患者多于反向转换(P=0.005)。
- 两种方案DAS28及其他疾病活动度指标无差异且随访期间稳定。
核心结论
- 在甲氨蝶呤应答不佳的RA患者中,三联疗法比甲氨蝶呤-依那西普治疗更持久。
- 考虑费用差异和相似结局,持久性差异支持传统联合方案作为甲氨蝶呤不足应答后的首选。
研究设计与样本
- 48周双盲非劣效随机试验,353例甲氨蝶呤应答不佳的RA患者随机接受三联疗法或甲氨蝶呤-依那西普。
- 24周无临床改善者换用替代治疗,289例参与额外至72周的开放标签延伸随访。
主要发现
- 开放标签随访平均±标准差 duration 为11±6个月。
- 三联疗法1年继续传统治疗的可能性为78%,甲氨蝶呤-依那西普为63%,多数治疗变更发生在随访开始时。
- 从甲氨蝶呤-依那西普转换为三联疗法的患者多于从三联疗法转换为甲氨蝶呤-依那西普(P=0.005)。
- 两种治疗的DAS28评分及其他疾病活动度指标无差异,随访期间稳定。
关键数值与推荐
- 三联疗法1年继续治疗可能性78% vs 甲氨蝶呤-依那西普63%。
- 治疗转换方向差异P=0.005。
临床怎么用
- 甲氨蝶呤应答不佳的RA患者可优先考虑三联疗法(甲氨蝶呤、柳氮磺吡啶、羟氯喹)而非甲氨蝶呤-依那西普。
- 选择方案时应结合费用差异与相似疗效及持久性数据综合决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although it is common for rheumatologists to initiate biologic agents after failure of methotrexate monotherapy in rheumatoid arthritis (RA), ample data support the initial use of combinations of conventional therapies in this clinical scenario. Our study explores the durability of triple therapy (methotrexate, sulfasalazine, and hydroxychloroquine) versus methotrexate-etanercept in RA. METHODS: RA patients with suboptimal response to methotrexate (n = 353) were randomized to either triple therapy or methotrexate-etanercept therapy in a 48-week, double-blinded, noninferiority trial. Patients without clinical improvement at 24 weeks were switched to the alternative treatment. Of the total, 289 participated in followup. We report treatment durability, Disease Activity Score in 28 joints (DAS28), and other measures during an open-label extension for an additional period up to 72 weeks. RESULTS: Mean ± SD duration of open-label followup was 11 ± 6 months. The likelihood of continuing conventional therapy at 1 year was 78% for triple therapy versus 63% for methotrexate-etanercept, with most treatment changes occurring at the start of followup. More patients changed from methotrexate-etanercept to triple therapy than from triple therapy to methotrexate-etanercept (P = 0.005). DAS28 scores and other disease activity measures were not different for the 2 treatments and were stable during followup. CONCLUSION: In RA patients with suboptimal methotrexate response randomized to receive triple therapy or methotrexate-etanercept, the former was found to be significantly more durable. Given cost differences and similar outcomes, the variable durability demonstrated provides additional evidence supporting conventional combinations over biologic agent combinations as the first choice after methotrexate inadequate response.
引用
- Peper SM, Lew R, Mikuls T, et al. Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept. Arthritis Care Res (Hoboken). 2017. PMID: 28388820. doi:10.1002/acr.23255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。